BNC Korea Co, Ltd
256840 | KO
Overview
Corporate Details
- ISIN(s):
- KR7256840000
- LEI:
- Country:
- South Korea
- Address:
- 대구광역시 달서구 성서공단로11길 62 대구테크노파크 벤처공장 1호관 405호(사무실),502호, 503호, 206호, 대구광역시
- Website:
- http://www.bnckorea.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Legal Proceedings Report
기타경영사항(자율공시) (의약품 회수·폐기 및 잠정 제조중지 등 명령 취소 소송 1심 판결)
|
Korean | 10.7 KB | ||
| 2025-08-26 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (CL-N, N 중국 국가약품감독관리국(NMPA) 품목허가 획득)
|
Korean | 12.6 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 2.1 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.6 MB | ||
| 2025-07-21 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (Cutegel 중국 국가약품감독관리국(NMPA) 품목허가 획득)
|
Korean | 8.4 KB | ||
| 2025-07-08 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 107.0 KB | ||
| 2025-05-30 00:00 |
Regulatory Filings
기타경영사항(자율공시)
|
Korean | 6.4 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.5 MB | ||
| 2025-04-29 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 16.5 KB | ||
| 2025-04-08 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 107.2 KB | ||
| 2025-03-31 00:00 |
AGM Information
정기주주총회결과
|
Korean | 19.9 KB | ||
| 2025-03-21 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 25.3 KB | ||
| 2025-03-21 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 2.1 MB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 195.0 KB | ||
| 2025-03-12 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 195.4 KB |
Automate Your Workflow. Get a real-time feed of all BNC Korea Co, Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for BNC Korea Co, Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BNC Korea Co, Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
United States of America
950130
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
United States of America
ACHV
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
United States of America
ACIU
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
United States of America
ACRS
Develops precision cancer therapies by matching patients to drugs using its proteomics platform.
United States of America
ACRV
United States of America
ACRV
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France
ALACT
France
ALACT
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM
United States of America
ATNM
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
United States of America
ACTU
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Sweden
ACUC
Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.
United States of America
ABOS
United States of America
ABOS